Equities research analysts at Zacks Investment Research downgraded shares of Akorn, Inc. (NASDAQ: AKRX) from an “outperform” rating to a “neutral” rating in a research note to clients and investors on Monday.
Akorn, Inc. manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, the Company has marketed and distributed vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company operates drug manufacturing facilities in Decatur, Illinois and Somerset, New Jersey. The Decatur, Illinois facilities operate as part of the Company, while the Somerset, New Jersey facility operates as Akorn (New Jersey), Inc., a wholly owned subsidiary of the Company.
Shares of Akorn, Inc. (NASDAQ: AKRX) traded up 1.42% during mid-day trading on Wednesday, hitting $5.73. Akorn, Inc. has a 52 week low of $1.27 and a 52 week high of $6.50. The stock’s 50-day moving average is $5.61 and its 200-day moving average is $4.23. On average, analysts predict that Akorn, Inc. will post $0.04 EPS next quarter. The company has a market cap of $537.6 million and a price-to-earnings ratio of N/A.
For more information about Zacks Investment Research’s equity research offerings, visit Zacks.com.
Stay on top of analysts’ coverage with American Banking & Market News’ daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day. Click Here to register.
